Does Fair Research Require Participants to Have Access to the Intervention or Knowledge Produced by the Study?

If Participants Help Produce the Research, Should They Have Access to What Comes Out of It?

Participants give researchers something valuable. They contribute time, information, biological samples, experiences, effort, and sometimes accept substantial risks or burdens. Those contributions can eventually produce knowledge, publications, interventions, technologies, or changes in practice.

What happens when the study ends?

Should participants be told what researchers discovered? If an experimental intervention works for them, should they continue receiving it? Should the community have access to the final intervention? Does fairness require all of these things?

These questions are related, but they should not be collapsed into a single idea of “giving participants the benefits.” Access to knowledge and continued access to an intervention involve different ethical considerations, different practical constraints, and sometimes different responsible parties.

Fairness Creates Responsibilities, but Not One Universal Access Rule

Access to Knowledge and Access to an Intervention Are Different Ethical Questions

Research produces more than one kind of benefit

A study may produce several outputs. It can generate general knowledge, individual research findings, a successful intervention, a dataset, a diagnostic method, a technology, a policy recommendation, or evidence that an intervention does not work.

These outputs should not all be treated as though they create identical obligations.

A survey can generate important knowledge without producing an intervention at all. A clinical trial may produce both knowledge and an intervention that some participants continue to need. Ethical analysis should follow what the particular study actually produces.

Participants should not simply disappear from the information chain

The 2024 Declaration of Helsinki states that all medical research participants should be given the option of being informed about the general outcome and results of the research. It separately requires researchers to make results of human-participant research publicly available, including negative and inconclusive findings as well as positive ones.

These requirements reflect different responsibilities. Public dissemination contributes to scientific transparency and social value. Giving participants an option to learn the general results recognizes their particular relationship to the research. A journal publication may satisfy part of the first responsibility without necessarily satisfying the second. A participant should not need a university subscription and a working knowledge of regression diagnostics merely to discover what became of a study they helped make possible.

CIOMS likewise treats dissemination as essential to the social value of research and includes dissemination of results within meaningful community engagement.

Returning general results is not the same as returning individual findings

This distinction is easy to miss.

A general research result might be: “The intervention reduced average symptom severity compared with the control condition.” An individual research result might concern a particular participant's genetic finding, laboratory result, imaging result, or other information specifically about that person.

Returning individual results raises additional questions about analytical validity, clinical significance, consent preferences, interpretability, possible psychological consequences, and whether appropriate clinical support is available. Those issues cannot be solved simply by applying a general principle that participants should know what the study found.

Researchers should therefore avoid promising “your results” when what they actually intend to provide is a summary of the study's overall findings.

Public availability and participant accessibility are not identical

The Declaration of Helsinki requires research results to be made publicly available. Public availability is important because unpublished research wastes participant contributions and can distort the evidence base when positive findings are more visible than negative or inconclusive ones.

Yet technically public information may still be practically inaccessible to participants. A paper can be difficult to locate, highly technical, written in an unfamiliar language, or inaccessible behind a subscription barrier.

Meaningful dissemination therefore asks a practical question: can the people to whom the information is being returned actually understand and use it?

CIOMS recommends involving communities in dissemination and emphasizes that community engagement should be meaningful and sustained. This can support communication formats suited to the population rather than assuming that scholarly publication is the only meaningful endpoint.

Access to a successful intervention raises a stronger and more specific question

Imagine a participant with a chronic condition who improves substantially while receiving an experimental intervention during a clinical trial. The trial ends. The participant still needs treatment, but the intervention is not yet commercially available.

The ethical question is no longer merely whether the participant should receive a summary of the findings. Ending the trial may also mean withdrawing something that appears to have provided meaningful benefit.

The 2024 Declaration of Helsinki addresses this situation directly. Before a clinical trial begins, sponsors and researchers must arrange post-trial provisions for participants who still need an intervention that the trial identifies as beneficial and reasonably safe. Those provisions may be provided by sponsors or researchers, healthcare systems, or governments. Exceptions require research ethics committee approval, and participants must be told about the post-trial provisions during informed consent.

The more specific question of when continued post-trial access is owed therefore goes beyond a general principle of reciprocity.

Post-trial access is not simply a reward for participation

It may be tempting to reason that participants “earned” the intervention by joining the trial. That framing is too simple.

Some participants may have received placebo or a comparator rather than the experimental intervention. Some interventions may ultimately prove ineffective or unsafe. Others may be useful only for particular participants. Continued provision may require clinical monitoring, regulatory authorization, manufacturing, funding, and a healthcare system capable of delivering it safely.

The ethical justification for post-trial access therefore concerns factors such as continuing clinical need, demonstrated benefit and reasonable safety, prior arrangements, fairness, and the relationship created by trial participation rather than an automatic entitlement to every product that happens to have been studied.

Not every participant must receive every downstream benefit of research

Research may eventually lead to a commercial product, policy change, educational program, diagnostic system, or intervention years after participation ends. Fairness does not imply that every participant must receive every eventual output free of charge.

That would be difficult to apply across the enormous variety of human research. Participants in an observational cohort might contribute data that eventually influence treatment guidelines decades later. Interview participants may contribute insights that shape policy. Basic research may contribute only indirectly to future interventions.

A more defensible approach is to ask what obligations arise from the particular research relationship rather than assuming that participation creates unlimited claims over all future value.

Justice matters most when participants help produce something they cannot realistically access

A particularly difficult situation arises when participants or communities bear research burdens specifically to test an intervention that is unlikely ever to be accessible to them.

This may occur because of price, infrastructure, regulatory availability, geographic location, or health-system limitations.

CIOMS treats access to resulting knowledge and interventions as part of the broader justice analysis in research. Its guidance on social value specifically identifies questions about who will have access to resulting knowledge and interventions as matters of justice and fairness.

This does not produce a universal rule that every intervention must be made free forever. It does mean that the relationship between those who bear research burdens and those who receive its benefits deserves examination before recruitment begins.

Community access and individual participant access are also different

A participant may have a claim to continued access because that particular person benefited from an intervention and still needs it. A broader community may have a different interest in eventual availability because its members contributed substantially to the research or because the research was justified as responsive to community health needs.

Those claims should not be treated as interchangeable.

The 2024 Declaration of Helsinki specifically frames its post-trial provision around participants who still need an intervention found beneficial and reasonably safe. Broader questions about community access involve responsiveness, justice, healthcare systems, sponsors, governments, affordability, and benefit sharing.

This is why community benefits from research deserve separate consideration rather than being assumed to follow automatically from individual post-trial obligations.

Access should be discussed before the study, not improvised after success

The timing matters.

If researchers wait until a successful trial ends to ask who will supply the intervention, who will pay, how long access will continue, and what happens if regulatory approval is delayed, they may discover that no stakeholder has accepted responsibility.

Both the Declaration of Helsinki and CIOMS emphasize advance planning. CIOMS calls for plans for continued access when an intervention has demonstrated significant benefit, including the modalities of access, parties involved in continued care, who will pay, and how long access will continue.

Access arrangements are therefore part of protocol design and ethical review, not merely an act of generosity after favorable results appear.

A Study Ends, but the Participant Still Needs What Worked

Common Misunderstandings About Access to Research Outputs

Plan Separately for Knowledge and Intervention Access

When writing a protocol, avoid a vague statement that “participants will benefit from the results.” Specify what access could realistically mean.

Participants should also be told accurately what will happen. Do not promise continued access when only a possibility exists, and do not imply that receiving study results means receiving the intervention itself.

For communities rather than individual participants, the analysis may broaden into what researchers continue to owe after data collection has finished.

Plan What Participants Can Access After the Research

Questions About Access to Research Results and Interventions

Participants Should Not Become Invisible Once Their Contribution Has Been Collected

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.